1. Home
  2. QUIK vs EVMN Comparison

QUIK vs EVMN Comparison

Compare QUIK & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QuickLogic Corporation

QUIK

QuickLogic Corporation

HOLD

Current Price

$8.23

Market Cap

196.7M

Sector

Technology

ML Signal

HOLD

Logo Evommune Inc.

EVMN

Evommune Inc.

HOLD

Current Price

$6.01

Market Cap

185.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QUIK
EVMN
Founded
1988
2020
Country
United States
United States
Employees
51
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
196.7M
185.1M
IPO Year
1997
2025

Fundamental Metrics

Financial Performance
Metric
QUIK
EVMN
Price
$8.23
$6.01
Analyst Decision
Buy
Buy
Analyst Count
4
12
Target Price
★ $23.00
$22.33
AVG Volume (30 Days)
160.7K
★ 911.5K
Earning Date
11-10-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 75.23
EPS
★ N/A
N/A
Revenue
★ $20,112,000.00
$13,000,000.00
Revenue This Year
$73.33
N/A
Revenue Next Year
$16.92
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 85.71
52 Week Low
$5.28
$4.94
52 Week High
$24.33
$33.20

Technical Indicators

Market Signals
Indicator
QUIK
EVMN
Relative Strength Index (RSI) 32.85 40.88
Support Level $7.38 $4.94
Resistance Level $10.14 $13.35
Average True Range (ATR) 0.45 0.57
MACD -0.05 0.29
Stochastic Oscillator 8.00 44.05

Price Performance

Historical Comparison
QUIK
EVMN

About QUIK QuickLogic Corporation

QuickLogic Corp is a fabless semiconductor company developing programmable logic semiconductor technologies, including embedded Field Programmable Gate Array (eFPGA) intellectual property (IP) and specialized FPGA devices. Its product offerings include the eFPGA IP licensing business and associated professional services, as well as a range of FPGA silicon products, including EOS, ArcticLink III, PolarPro 3, PolarPro II, PolarPro, and Eclipse II products, among others. The company's customers come from various markets, including aerospace and defense, industrial and infrastructure systems, data processing and computing platforms, and certain embedded and edge computing applications. Geographically, it generates maximum revenue from North America and the rest from Asia Pacific and Europe.

About EVMN Evommune Inc.

Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.

Share on Social Networks: